Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases in the areas of various orphan and niche indications primarily in North America and the European Union. It offers Raxone/Catena for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) and Duchenne Muscular Dystrophy (DMD). The company also develops Raxone/Catena for treating patients with primary progressive Multiple Sclerosis. It also develops omigapil that is in Phase I trial for the treatment of Congenital Muscular Dystrophies. The company has a collaboration agreement with the US patient advocacy organization for a survey- based benefit/risk evaluation in DMD. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Liestal, Switzerland.
(SANN:SIX Swiss Ex)
Phone: 41 61 906 89 50
|No competitor information is available for SANN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact SANTHERA PHARMACEUTICALS-REG, please visit www.santhera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.